Details for New Drug Application (NDA): 208537
✉ Email this page to a colleague
The generic ingredient in TICAGRELOR is ticagrelor. There are twenty-one drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the ticagrelor profile page.
Summary for 208537
| Tradename: | TICAGRELOR |
| Applicant: | Invagen Pharms |
| Ingredient: | ticagrelor |
| Patents: | 0 |
Pharmacology for NDA: 208537
| Mechanism of Action | Cytochrome P450 3A4 Inhibitors P-Glycoprotein Inhibitors P2Y12 Receptor Antagonists |
| Physiological Effect | Decreased Platelet Aggregation |
Suppliers and Packaging for NDA: 208537
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TICAGRELOR | ticagrelor | TABLET;ORAL | 208537 | ANDA | Aphena Pharma Solutions - Tennessee, LLC | 71610-914 | 71610-914-41 | 5400 TABLET, FILM COATED in 1 BOTTLE (71610-914-41) |
| TICAGRELOR | ticagrelor | TABLET;ORAL | 208537 | ANDA | Exelan Pharmaceuticals, Inc | 76282-550 | 76282-550-01 | 100 TABLET, FILM COATED in 1 BOTTLE (76282-550-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 90MG | ||||
| Approval Date: | May 5, 2025 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 60MG | ||||
| Approval Date: | Oct 28, 2025 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
